{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,21]],"date-time":"2026-10-21T21:58:48Z","timestamp":1792619928671,"version":"4.5.0"},"reference-count":49,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2022,5,19]],"date-time":"2022-05-19T00:00:00Z","timestamp":1652918400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2022,5,19]],"date-time":"2022-05-19T00:00:00Z","timestamp":1652918400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Sci Rep"],"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:p>\n                    Orexin, a neuropeptide, performs various physiological functions, including the regulation of emotion, feeding, metabolism, respiration, and sleep\/wakefulness, by activating the orexin 1 receptor and orexin 2 receptor (OX2R). Owing to the pivotal role of OX2R in wakefulness and other biological functions, OX2R agonists are being developed. A detailed understanding of OX2R protein distribution is essential for determining the mechanisms of action of OX2R agonists; however, this has been hindered by the lack of selective antibodies. In this study, we first confirmed the OX2R-selective binding of [\n                    <jats:sup>3<\/jats:sup>\n                    H]-EMPA in in vitro autoradiography studies, using brain slices from OX2R knockout mice and their wild-type littermates. Subsequently, OX2R protein distribution in rats was comprehensively assessed in 51 brain regions and 10 peripheral tissues using in vitro autoradiography with [\n                    <jats:sup>3<\/jats:sup>\n                    H]-EMPA. The widespread distribution of OX2R protein, including that in previously unrecognized regions of the retrosplenial cortex, was identified. In contrast, OX2R protein expression was negligible\/very low in peripheral tissues, suggesting that orexin exerts OX2R-dependent physiological functions primarily through activation of the central nervous system. These findings will be useful for understanding the wide range of biological functions of OX2R and the application of OX2R agonists in various disorders.\n                  <\/jats:p>","DOI":"10.1038\/s41598-022-12601-x","type":"journal-article","created":{"date-parts":[[2022,5,19]],"date-time":"2022-05-19T10:03:50Z","timestamp":1652954630000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":31,"title":["Orexin 2 receptor (OX2R) protein distribution measured by autoradiography using radiolabeled OX2R-selective antagonist EMPA in rodent brain and peripheral tissues"],"prefix":"10.1038","volume":"12","author":[{"given":"Kayo","family":"Mitsukawa","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Haruhide","family":"Kimura","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2022,5,19]]},"reference":[{"key":"12601_CR1","doi-asserted-by":"publisher","first-page":"573","DOI":"10.1016\/s0092-8674(00)80949-6","volume":"92","author":"T Sakurai","year":"1998","unstructured":"Sakurai, T. et al. Orexins and orexin receptors: A family of hypothalamic neuropeptides and G protein-coupled receptors that regulate feeding behavior. Cell 92, 573\u2013585. https:\/\/doi.org\/10.1016\/s0092-8674(00)80949-6 (1998).","journal-title":"Cell"},{"key":"12601_CR2","doi-asserted-by":"publisher","first-page":"322","DOI":"10.1073\/pnas.95.1.322","volume":"95","author":"L de Lecea","year":"1998","unstructured":"de Lecea, L. et al. The hypocretins: Hypothalamus-specific peptides with neuroexcitatory activity. Proc. Natl. Acad. Sci. U.S.A. 95, 322\u2013327. https:\/\/doi.org\/10.1073\/pnas.95.1.322 (1998).","journal-title":"Proc. Natl. Acad. Sci. U.S.A."},{"key":"12601_CR3","doi-asserted-by":"publisher","first-page":"243","DOI":"10.1016\/s0006-8993(99)01336-0","volume":"827","author":"T Nambu","year":"1999","unstructured":"Nambu, T. et al. Distribution of orexin neurons in the adult rat brain. Brain Res. 827, 243\u2013260. https:\/\/doi.org\/10.1016\/s0006-8993(99)01336-0 (1999).","journal-title":"Brain Res."},{"key":"12601_CR4","doi-asserted-by":"publisher","first-page":"9996","DOI":"10.1523\/JNEUROSCI.18-23-09996.1998","volume":"18","author":"C Peyron","year":"1998","unstructured":"Peyron, C. et al. Neurons containing hypocretin (orexin) project to multiple neuronal systems. J. Neurosci. 18, 9996\u201310015 (1998).","journal-title":"J. Neurosci."},{"key":"12601_CR5","doi-asserted-by":"publisher","first-page":"39","DOI":"10.1016\/S0140-6736(99)05582-8","volume":"355","author":"S Nishino","year":"2000","unstructured":"Nishino, S., Ripley, B., Overeem, S., Lammers, G. J. & Mignot, E. Hypocretin (orexin) deficiency in human narcolepsy. Lancet 355, 39\u201340. https:\/\/doi.org\/10.1016\/S0140-6736(99)05582-8 (2000).","journal-title":"Lancet"},{"key":"12601_CR6","doi-asserted-by":"publisher","first-page":"991","DOI":"10.1038\/79690","volume":"6","author":"C Peyron","year":"2000","unstructured":"Peyron, C. et al. A mutation in a case of early onset narcolepsy and a generalized absence of hypocretin peptides in human narcoleptic brains. Nat. Med. 6, 991\u2013997. https:\/\/doi.org\/10.1038\/79690 (2000).","journal-title":"Nat. Med."},{"key":"12601_CR7","doi-asserted-by":"publisher","first-page":"469","DOI":"10.1016\/s0896-6273(00)00058-1","volume":"27","author":"TC Thannickal","year":"2000","unstructured":"Thannickal, T. C. et al. Reduced number of hypocretin neurons in human narcolepsy. Neuron 27, 469\u2013474. https:\/\/doi.org\/10.1016\/s0896-6273(00)00058-1 (2000).","journal-title":"Neuron"},{"key":"12601_CR8","doi-asserted-by":"publisher","first-page":"519","DOI":"10.1038\/s41582-019-0226-9","volume":"15","author":"CLA Bassetti","year":"2019","unstructured":"Bassetti, C. L. A. et al. Narcolepsy\u2014Clinical spectrum, aetiopathophysiology, diagnosis and treatment. Nat. Rev. Neurol. 15, 519\u2013539. https:\/\/doi.org\/10.1038\/s41582-019-0226-9 (2019).","journal-title":"Nat. Rev. Neurol."},{"key":"12601_CR9","doi-asserted-by":"publisher","first-page":"9","DOI":"10.1016\/j.sleep.2014.10.002","volume":"16","author":"MJ Thorpy","year":"2015","unstructured":"Thorpy, M. J. & Dauvilliers, Y. Clinical and practical considerations in the pharmacologic management of narcolepsy. Sleep Med. 16, 9\u201318. https:\/\/doi.org\/10.1016\/j.sleep.2014.10.002 (2015).","journal-title":"Sleep Med."},{"key":"12601_CR10","doi-asserted-by":"publisher","first-page":"28","DOI":"10.3389\/fnbeh.2013.00028","volume":"7","author":"N Tsujino","year":"2013","unstructured":"Tsujino, N. & Sakurai, T. Role of orexin in modulating arousal, feeding, and motivation. Front. Behav. Neurosci. 7, 28. https:\/\/doi.org\/10.3389\/fnbeh.2013.00028 (2013).","journal-title":"Front. Behav. Neurosci."},{"key":"12601_CR11","doi-asserted-by":"publisher","first-page":"171","DOI":"10.1038\/nrn2092","volume":"8","author":"T Sakurai","year":"2007","unstructured":"Sakurai, T. The neural circuit of orexin (hypocretin): Maintaining sleep and wakefulness. Nat. Rev. Neurosci. 8, 171\u2013181. https:\/\/doi.org\/10.1038\/nrn2092 (2007).","journal-title":"Nat. Rev. Neurosci."},{"key":"12601_CR12","doi-asserted-by":"publisher","first-page":"365","DOI":"10.1016\/s0092-8674(00)81965-0","volume":"98","author":"L Lin","year":"1999","unstructured":"Lin, L. et al. The sleep disorder canine narcolepsy is caused by a mutation in the hypocretin (orexin) receptor 2 gene. Cell 98, 365\u2013376. https:\/\/doi.org\/10.1016\/s0092-8674(00)81965-0 (1999).","journal-title":"Cell"},{"key":"12601_CR13","doi-asserted-by":"publisher","first-page":"719","DOI":"10.1038\/nrn3837","volume":"15","author":"T Sakurai","year":"2014","unstructured":"Sakurai, T. The role of orexin in motivated behaviours. Nat. Rev. Neurosci. 15, 719\u2013731. https:\/\/doi.org\/10.1038\/nrn3837 (2014).","journal-title":"Nat. Rev. Neurosci."},{"key":"12601_CR14","doi-asserted-by":"publisher","first-page":"243","DOI":"10.1146\/annurev-pharmtox-010510-100528","volume":"51","author":"TE Scammell","year":"2011","unstructured":"Scammell, T. E. & Winrow, C. J. Orexin receptors: Pharmacology and therapeutic opportunities. Annu. Rev. Pharmacol. Toxicol. 51, 243\u2013266. https:\/\/doi.org\/10.1146\/annurev-pharmtox-010510-100528 (2011).","journal-title":"Annu. Rev. Pharmacol. Toxicol."},{"key":"12601_CR15","doi-asserted-by":"publisher","DOI":"10.1016\/j.pbb.2019.172794","volume":"187","author":"H Yukitake","year":"2019","unstructured":"Yukitake, H. et al. TAK-925, an orexin 2 receptor-selective agonist, shows robust wake-promoting effects in mice. Pharmacol. Biochem. Behav. 187, 172794. https:\/\/doi.org\/10.1016\/j.pbb.2019.172794 (2019).","journal-title":"Pharmacol. Biochem. Behav."},{"key":"12601_CR16","doi-asserted-by":"publisher","first-page":"6","DOI":"10.1002\/cne.1190","volume":"435","author":"JN Marcus","year":"2001","unstructured":"Marcus, J. N. et al. Differential expression of orexin receptors 1 and 2 in the rat brain. J. Comp. Neurol. 435, 6\u201325. https:\/\/doi.org\/10.1002\/cne.1190 (2001).","journal-title":"J. Comp. Neurol."},{"key":"12601_CR17","doi-asserted-by":"publisher","first-page":"71","DOI":"10.1016\/s0014-5793(98)01266-6","volume":"438","author":"P Trivedi","year":"1998","unstructured":"Trivedi, P., Yu, H., MacNeil, D. J., Van der Ploeg, L. H. & Guan, X. M. Distribution of orexin receptor mRNA in the rat brain. FEBS Lett. 438, 71\u201375. https:\/\/doi.org\/10.1016\/s0014-5793(98)01266-6 (1998).","journal-title":"FEBS Lett."},{"key":"12601_CR18","doi-asserted-by":"publisher","first-page":"3324","DOI":"10.1210\/endo.142.8.8299","volume":"142","author":"O Johren","year":"2001","unstructured":"Johren, O., Neidert, S. J., Kummer, M., Dendorfer, A. & Dominiak, P. Prepro-orexin and orexin receptor mRNAs are differentially expressed in peripheral tissues of male and female rats. Endocrinology 142, 3324\u20133331. https:\/\/doi.org\/10.1210\/endo.142.8.8299 (2001).","journal-title":"Endocrinology"},{"key":"12601_CR19","doi-asserted-by":"publisher","first-page":"362","DOI":"10.1021\/cn500281t","volume":"6","author":"I Manuel","year":"2015","unstructured":"Manuel, I. et al. Neurotransmitter receptor localization: From autoradiography to imaging mass spectrometry. ACS Chem. Neurosci. 6, 362\u2013373. https:\/\/doi.org\/10.1021\/cn500281t (2015).","journal-title":"ACS Chem. Neurosci."},{"key":"12601_CR20","doi-asserted-by":"publisher","first-page":"1326","DOI":"10.1111\/j.1476-5381.2009.00127.x","volume":"156","author":"P Malherbe","year":"2009","unstructured":"Malherbe, P. et al. Biochemical and behavioural characterization of EMPA, a novel high-affinity, selective antagonist for the OX(2) receptor. Br. J. Pharmacol. 156, 1326\u20131341. https:\/\/doi.org\/10.1111\/j.1476-5381.2009.00127.x (2009).","journal-title":"Br. J. Pharmacol."},{"key":"12601_CR21","doi-asserted-by":"publisher","first-page":"96","DOI":"10.1016\/s0006-3223(02)01740-7","volume":"54","author":"RM Salomon","year":"2003","unstructured":"Salomon, R. M. et al. Diurnal variation of cerebrospinal fluid hypocretin-1 (Orexin-A) levels in control and depressed subjects. Biol. Psychiatry 54, 96\u2013104. https:\/\/doi.org\/10.1016\/s0006-3223(02)01740-7 (2003).","journal-title":"Biol. Psychiatry"},{"key":"12601_CR22","doi-asserted-by":"publisher","first-page":"1075","DOI":"10.1046\/j.0953-816x.2001.01725.x","volume":"14","author":"Y Yoshida","year":"2001","unstructured":"Yoshida, Y. et al. Fluctuation of extracellular hypocretin-1 (orexin A) levels in the rat in relation to the light\u2013dark cycle and sleep-wake activities. Eur. J. Neurosci. 14, 1075\u20131081. https:\/\/doi.org\/10.1046\/j.0953-816x.2001.01725.x (2001).","journal-title":"Eur. J. Neurosci."},{"key":"12601_CR23","doi-asserted-by":"publisher","first-page":"3555","DOI":"10.1523\/JNEUROSCI.23-08-03555.2003","volume":"23","author":"JM Zeitzer","year":"2003","unstructured":"Zeitzer, J. M. et al. Circadian and homeostatic regulation of hypocretin in a primate model: Implications for the consolidation of wakefulness. J. Neurosci. 23, 3555\u20133560 (2003).","journal-title":"J. Neurosci."},{"key":"12601_CR24","doi-asserted-by":"publisher","first-page":"4225","DOI":"10.1016\/j.bmcl.2004.06.032","volume":"14","author":"LC McAtee","year":"2004","unstructured":"McAtee, L. C. et al. Novel substituted 4-phenyl-[1,3]dioxanes: Potent and selective orexin receptor 2 (OX(2)R) antagonists. Bioorg. Med. Chem. Lett. 14, 4225\u20134229. https:\/\/doi.org\/10.1016\/j.bmcl.2004.06.032 (2004).","journal-title":"Bioorg. Med. Chem. Lett."},{"key":"12601_CR25","doi-asserted-by":"publisher","first-page":"1999","DOI":"10.1038\/npp.2012.48","volume":"37","author":"L Piccoli","year":"2012","unstructured":"Piccoli, L. et al. Role of orexin-1 receptor mechanisms on compulsive food consumption in a model of binge eating in female rats. Neuropsychopharmacology 37, 1999\u20132011. https:\/\/doi.org\/10.1038\/npp.2012.48 (2012).","journal-title":"Neuropsychopharmacology"},{"key":"12601_CR26","doi-asserted-by":"publisher","first-page":"4497","DOI":"10.1016\/j.bmcl.2003.08.038","volume":"13","author":"M Hirose","year":"2003","unstructured":"Hirose, M. et al. N-acyl 6,7-dimethoxy-1,2,3,4-tetrahydroisoquinoline: The first orexin-2 receptor selective non-peptidic antagonist. Bioorg. Med. Chem. Lett. 13, 4497\u20134499. https:\/\/doi.org\/10.1016\/j.bmcl.2003.08.038 (2003).","journal-title":"Bioorg. Med. Chem. Lett."},{"key":"12601_CR27","doi-asserted-by":"publisher","first-page":"13078","DOI":"10.1038\/s41598-021-91659-5","volume":"11","author":"DG de Almeida-Filho","year":"2021","unstructured":"de Almeida-Filho, D. G. et al. Hippocampus\u2013retrosplenial cortex interaction is increased during phasic REM and contributes to memory consolidation. Sci. Rep. 11, 13078. https:\/\/doi.org\/10.1038\/s41598-021-91659-5 (2021).","journal-title":"Sci. Rep."},{"key":"12601_CR28","doi-asserted-by":"publisher","first-page":"8003","DOI":"10.1523\/JNEUROSCI.0026-17.2017","volume":"37","author":"BDV Koike","year":"2017","unstructured":"Koike, B. D. V. et al. Electrophysiological evidence that the retrosplenial cortex displays a strong and specific activation phased with hippocampal theta during paradoxical (REM) sleep. J. Neurosci. 37, 8003\u20138013. https:\/\/doi.org\/10.1523\/JNEUROSCI.0026-17.2017 (2017).","journal-title":"J. Neurosci."},{"key":"12601_CR29","doi-asserted-by":"publisher","first-page":"432","DOI":"10.1016\/j.celrep.2019.12.038","volume":"30","author":"AN Opalka","year":"2020","unstructured":"Opalka, A. N., Huang, W. Q., Liu, J., Liang, H. & Wang, D. V. Hippocampal ripple coordinates retrosplenial inhibitory neurons during slow-wave sleep. Cell Rep. 30, 432-441 e433. https:\/\/doi.org\/10.1016\/j.celrep.2019.12.038 (2020).","journal-title":"Cell Rep."},{"key":"12601_CR30","doi-asserted-by":"publisher","first-page":"747","DOI":"10.1016\/j.neuron.2017.01.014","volume":"93","author":"TE Scammell","year":"2017","unstructured":"Scammell, T. E., Arrigoni, E. & Lipton, J. O. Neural circuitry of wakefulness and sleep. Neuron 93, 747\u2013765. https:\/\/doi.org\/10.1016\/j.neuron.2017.01.014 (2017).","journal-title":"Neuron"},{"key":"12601_CR31","doi-asserted-by":"publisher","first-page":"435","DOI":"10.1097\/00001756-200102120-00048","volume":"12","author":"EE Abrahamson","year":"2001","unstructured":"Abrahamson, E. E., Leak, R. K. & Moore, R. Y. The suprachiasmatic nucleus projects to posterior hypothalamic arousal systems. NeuroReport 12, 435\u2013440. https:\/\/doi.org\/10.1097\/00001756-200102120-00048 (2001).","journal-title":"NeuroReport"},{"key":"12601_CR32","doi-asserted-by":"publisher","first-page":"727","DOI":"10.1016\/j.neuroscience.2004.07.049","volume":"129","author":"T Deboer","year":"2004","unstructured":"Deboer, T. et al. Convergence of circadian and sleep regulatory mechanisms on hypocretin-1. Neuroscience 129, 727\u2013732. https:\/\/doi.org\/10.1016\/j.neuroscience.2004.07.049 (2004).","journal-title":"Neuroscience"},{"key":"12601_CR33","doi-asserted-by":"publisher","first-page":"619","DOI":"10.1093\/sleep\/27.4.619","volume":"27","author":"S Zhang","year":"2004","unstructured":"Zhang, S. et al. Lesions of the suprachiasmatic nucleus eliminate the daily rhythm of hypocretin-1 release. Sleep 27, 619\u2013627. https:\/\/doi.org\/10.1093\/sleep\/27.4.619 (2004).","journal-title":"Sleep"},{"key":"12601_CR34","doi-asserted-by":"publisher","first-page":"3607","DOI":"10.1523\/JNEUROSCI.3388-13.2014","volume":"34","author":"MD Belle","year":"2014","unstructured":"Belle, M. D. et al. Acute suppressive and long-term phase modulation actions of orexin on the mammalian circadian clock. J. Neurosci. 34, 3607\u20133621. https:\/\/doi.org\/10.1523\/JNEUROSCI.3388-13.2014 (2014).","journal-title":"J. Neurosci."},{"key":"12601_CR35","doi-asserted-by":"publisher","first-page":"163","DOI":"10.3389\/fphar.2013.00163","volume":"4","author":"AC Equihua","year":"2013","unstructured":"Equihua, A. C., De La Herran-Arita, A. K. & Drucker-Colin, R. Orexin receptor antagonists as therapeutic agents for insomnia. Front. Pharmacol. 4, 163. https:\/\/doi.org\/10.3389\/fphar.2013.00163 (2013).","journal-title":"Front. Pharmacol."},{"key":"12601_CR36","doi-asserted-by":"publisher","first-page":"6518","DOI":"10.1523\/JNEUROSCI.6506-10.2011","volume":"31","author":"M Mieda","year":"2011","unstructured":"Mieda, M. et al. Differential roles of orexin receptor-1 and -2 in the regulation of non-REM and REM sleep. J. Neurosci. 31, 6518\u20136526. https:\/\/doi.org\/10.1523\/JNEUROSCI.6506-10.2011 (2011).","journal-title":"J. Neurosci."},{"key":"12601_CR37","doi-asserted-by":"publisher","first-page":"4808","DOI":"10.1210\/jcem.86.10.7921","volume":"86","author":"HS Randeva","year":"2001","unstructured":"Randeva, H. S., Karteris, E., Grammatopoulos, D. & Hillhouse, E. W. Expression of orexin-A and functional orexin type 2 receptors in the human adult adrenals: Implications for adrenal function and energy homeostasis. J. Clin. Endocrinol. Metab. 86, 4808\u20134813. https:\/\/doi.org\/10.1210\/jcem.86.10.7921 (2001).","journal-title":"J. Clin. Endocrinol. Metab."},{"key":"12601_CR38","doi-asserted-by":"publisher","first-page":"778","DOI":"10.1210\/jcem.86.2.7233","volume":"86","author":"G Mazzocchi","year":"2001","unstructured":"Mazzocchi, G., Malendowicz, L. K., Gottardo, L., Aragona, F. & Nussdorfer, G. G. Orexin A stimulates cortisol secretion from human adrenocortical cells through activation of the adenylate cyclase-dependent signaling cascade. J. Clin. Endocrinol. Metab. 86, 778\u2013782. https:\/\/doi.org\/10.1210\/jcem.86.2.7233 (2001).","journal-title":"J. Clin. Endocrinol. Metab."},{"key":"12601_CR39","doi-asserted-by":"publisher","first-page":"R1601","DOI":"10.1152\/ajpregu.91034.2008","volume":"297","author":"J Wenzel","year":"2009","unstructured":"Wenzel, J. et al. Hypocretin\/orexin increases the expression of steroidogenic enzymes in human adrenocortical NCI H295R cells. Am. J. Physiol. Regul. Integr. Comp. Physiol. 297, R1601\u2013R1609. https:\/\/doi.org\/10.1152\/ajpregu.91034.2008 (2009).","journal-title":"Am. J. Physiol. Regul. Integr. Comp. Physiol."},{"key":"12601_CR40","doi-asserted-by":"publisher","first-page":"423","DOI":"10.1016\/j.jsbmb.2005.05.003","volume":"96","author":"A Ziolkowska","year":"2005","unstructured":"Ziolkowska, A. et al. Orexins stimulate glucocorticoid secretion from cultured rat and human adrenocortical cells, exclusively acting via the OX1 receptor. J. Steroid Biochem. Mol. Biol. 96, 423\u2013429. https:\/\/doi.org\/10.1016\/j.jsbmb.2005.05.003 (2005).","journal-title":"J. Steroid Biochem. Mol. Biol."},{"key":"12601_CR41","doi-asserted-by":"publisher","first-page":"953","DOI":"10.1093\/sleep\/26.8.953","volume":"26","author":"N Fujiki","year":"2003","unstructured":"Fujiki, N., Yoshida, Y., Ripley, B., Mignot, E. & Nishino, S. Effects of IV and ICV hypocretin-1 (orexin A) in hypocretin receptor-2 gene mutated narcoleptic dogs and IV hypocretin-1 replacement therapy in a hypocretin-ligand-deficient narcoleptic dog. Sleep 26, 953\u2013959. https:\/\/doi.org\/10.1093\/sleep\/26.8.953 (2003).","journal-title":"Sleep"},{"key":"12601_CR42","doi-asserted-by":"publisher","first-page":"1749","DOI":"10.1212\/wnl.56.12.1749","volume":"56","author":"MA Dalal","year":"2001","unstructured":"Dalal, M. A. et al. Normal plasma levels of orexin A (hypocretin-1) in narcoleptic patients. Neurology 56, 1749\u20131751. https:\/\/doi.org\/10.1212\/wnl.56.12.1749 (2001).","journal-title":"Neurology"},{"key":"12601_CR43","doi-asserted-by":"publisher","first-page":"710","DOI":"10.3389\/fendo.2018.00710","volume":"9","author":"KA Makela","year":"2018","unstructured":"Makela, K. A. et al. Plasma Orexin-A levels do not undergo circadian rhythm in young healthy male subjects. Front. Endocrinol. (Lausanne) 9, 710. https:\/\/doi.org\/10.3389\/fendo.2018.00710 (2018).","journal-title":"Front. Endocrinol. (Lausanne)"},{"key":"12601_CR44","doi-asserted-by":"publisher","first-page":"477","DOI":"10.1038\/s41598-018-36942-8","volume":"9","author":"N Sakai","year":"2019","unstructured":"Sakai, N., Matsumura, M., Lin, L., Mignot, E. & Nishino, S. HPLC analysis of CSF hypocretin-1 in type 1 and 2 narcolepsy. Sci. Rep. 9, 477. https:\/\/doi.org\/10.1038\/s41598-018-36942-8 (2019).","journal-title":"Sci. Rep."},{"key":"12601_CR45","doi-asserted-by":"publisher","first-page":"9323","DOI":"10.1021\/acs.analchem.9b02710","volume":"91","author":"K Bardsen","year":"2019","unstructured":"Bardsen, K. et al. Considerably lower levels of hypocretin-1 in cerebrospinal fluid is revealed by a novel mass spectrometry method compared with standard radioimmunoassay. Anal. Chem. 91, 9323\u20139329. https:\/\/doi.org\/10.1021\/acs.analchem.9b02710 (2019).","journal-title":"Anal. Chem."},{"key":"12601_CR46","doi-asserted-by":"publisher","first-page":"25162","DOI":"10.1038\/srep25162","volume":"6","author":"C Hirtz","year":"2016","unstructured":"Hirtz, C. et al. From radioimmunoassay to mass spectrometry: A new method to quantify orexin-A (hypocretin-1) in cerebrospinal fluid. Sci. Rep. 6, 25162. https:\/\/doi.org\/10.1038\/srep25162 (2016).","journal-title":"Sci. Rep."},{"key":"12601_CR47","doi-asserted-by":"publisher","first-page":"34","DOI":"10.1016\/j.clinbiochem.2021.01.009","volume":"90","author":"M Lindstrom","year":"2021","unstructured":"Lindstrom, M. et al. Orexin-A measurement in narcolepsy: A stability study and a comparison of LC-MS\/MS and immunoassays. Clin. Biochem. 90, 34\u201339. https:\/\/doi.org\/10.1016\/j.clinbiochem.2021.01.009 (2021).","journal-title":"Clin. Biochem."},{"key":"12601_CR48","volume-title":"The Mouse Brain in Stereotaxic Coordinates","author":"KBJF George Paxinos","year":"2012","unstructured":"George Paxinos, K. B. J. F. The Mouse Brain in Stereotaxic Coordinates 4th edn. (Academic Press, 2012).","edition":"4"},{"key":"12601_CR49","volume-title":"The Rat Brain Atlas in Stereotaxic Coordinates","author":"CW George Paxinos","year":"1998","unstructured":"George Paxinos, C. W. The Rat Brain Atlas in Stereotaxic Coordinates 4th edn. (Academic Press, 1998).","edition":"4"}],"container-title":["Scientific Reports"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.nature.com\/articles\/s41598-022-12601-x.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41598-022-12601-x","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41598-022-12601-x.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,11,24]],"date-time":"2022-11-24T22:32:29Z","timestamp":1669329149000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.nature.com\/articles\/s41598-022-12601-x"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,5,19]]},"references-count":49,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2022,12]]}},"alternative-id":["12601"],"URL":"https:\/\/doi.org\/10.1038\/s41598-022-12601-x","relation":{"has-preprint":[{"id-type":"doi","id":"10.21203\/rs.3.rs-1144161\/v1","asserted-by":"object"}]},"ISSN":["2045-2322"],"issn-type":[{"value":"2045-2322","type":"electronic"}],"subject":[],"published":{"date-parts":[[2022,5,19]]},"assertion":[{"value":"6 December 2021","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"13 May 2022","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"19 May 2022","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"K.M. and H. K. are employees of Takeda Pharmaceutical Company Limited and own stock or stock options.","order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"8473"}}